Hangzhou Minsheng Healthcare Co Ltd (301507) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Hangzhou Minsheng Healthcare Co Ltd stock ¥3.66, price ¥11.67, that is 68.6% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
38‑month range ¥10.54 – ¥31.88 · fair‑value band ¥3.52 – ¥4.02 · the ¥11.67 price screens above the ¥3.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Hangzhou Minsheng Healthcare Co in your weekly email
Every Wednesday you see whether Hangzhou Minsheng Healthcare Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hangzhou Minsheng Healthcare Co., Ltd. engages in the research, development, production, and sale of vitamins and mineral supplements, OTC drugs, and health foods in China.
Show moreShow less
The company offers healthy products, such as fish and algae oil gel candy, collagen peptide vitamin D calcium chewable tablets, blueberry lutein ester candy tablets, and probiotic solid beverage.
It also provides multivitamin, vitamin, and zinc selenium with mineral tablets; and glucosamine chondroitin colostrum protein chewable, vitamin soft capsules and chewable, iron folic acid, melatonin, coenzyme soft capsules, and calcium magnesium vitamin D tablets.
The company offers its product under the 21 SUPER-VITA brand name. Hangzhou Minsheng Healthcare Co., Ltd. was founded in 1926 and is based in Hangzhou, China.
Stock analysis
Hangzhou Minsheng Healthcare Co Ltd (301507) currently trades at ¥11.67, while our model-based Fair Value estimate is ¥3.66, 69% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥6.77 per share, and 1 of the 17 models we run sit above the ¥11.67 price.
Bear case: the DCF Models group reads lowest at ¥1.31, and 16 of the 17 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥3.52 (bear) to ¥4.02 (bull), the price of ¥11.67 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hangzhou Minsheng Healthcare Co Ltd reported revenue of 782M CNY in FY2025 versus 490M CNY in FY2021, a compound +12.4%/yr. Reported net income was 119M CNY in FY2025, compounding +14.0%/yr from FY2021.
Key figures
Market cap 4.2B CNY (≈ $624M) Small · P/E ratio 44.9 · P/S ratio 4.61 · EPS (TTM) ¥0.2600 · Dividend yield 1.3% · Net margin 9.8% · Return on equity 5.3% · Return on assets (EBIT) 7.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −69%, 301507 screens richer than that median.
Fair Value models
Bear¥3.52Fair Value ¥3.66Bull¥4.02
Price ¥11.67 · Downside -68.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.0940 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.49/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+21.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.9%
Dividend (yield on the price)1.3%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 12%
Compare Hangzhou Minsheng Healthcare Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 1/12 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−68.6% · Bottom 25%
Profitability
Return on equity (12 months)5.3% · Below median
Return on assets5.9% · Below median
Net margin (12 months)9.8% · Below median
Operating margin (12 months)3.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)30.0% · Top 25%
Dividend yield (12 months)1.3% · Below median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (12 months)44.9× · Priciest 25%
P/B2.60× · Pricier than median
P/S (12 months)4.61× · Pricier than median
EV/EBITDA30.1× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)100· sector 34
PAST (return on equity)21· sector 41
HEALTH (low debt)0· sector 93
DIVIDEND (yield)26· sector 38
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hangzhou Minsheng Healthcare Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/301507
Frequently asked questions
Is Hangzhou Minsheng Healthcare Co Ltd (301507) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥3.66 versus a price of ¥11.67, about 69% lower (overvalued).
What is the fair value of 301507?
Our model-based fair value for Hangzhou Minsheng Healthcare Co Ltd is ¥3.66 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥11.67.
What is the quality score of 301507?
Hangzhou Minsheng Healthcare Co Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hangzhou Minsheng Healthcare Co Ltd (301507)?
Our model-based price target is the fair value of ¥3.66 (as of Nov 5, 2026) from 17 valuation models. Cautious scenario ¥3.52, optimistic scenario ¥4.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Hangzhou Minsheng Healthcare Co Ltd stock forecast for 2026?
Our models put fair value at ¥3.66, about 69% lower versus a price of ¥11.67 (overvalued). Cautious scenario ¥3.52, optimistic scenario ¥4.02. The calculation is refreshed regularly with new filings.
What is the revenue of Hangzhou Minsheng Healthcare Co Ltd (301507)?
Hangzhou Minsheng Healthcare Co Ltd reported trailing-twelve-month revenue of about 903M CNY (latest available figure, as of Nov 5, 2026).
Does Hangzhou Minsheng Healthcare Co Ltd pay a dividend?
Hangzhou Minsheng Healthcare Co Ltd currently shows a dividend yield of 1.29% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Hangzhou Minsheng Healthcare Co Ltd (301507) and when is the ex-dividend date?
Hangzhou Minsheng Healthcare Co Ltd pays a dividend of ¥0.15 per share a year, a dividend yield of 1.3%. The last ex-dividend date was Jun 9, 2026. The payout ratio is 57.7% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Hangzhou Minsheng Healthcare Co Ltd (301507)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hangzhou Minsheng Healthcare Co Ltd it is ¥3.66 per share (as of Nov 5, 2026), against a price of ¥11.67. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Hangzhou Minsheng Healthcare Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 301507 trades above its calculated fair value: price ¥11.67, fair value ¥3.66, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301507?
No. The price is what the market pays today (¥11.67); the fair value is what the company's own numbers justify (¥3.66). For Hangzhou Minsheng Healthcare Co Ltd the two are ¥8.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hangzhou Minsheng Healthcare Co Ltd worth?
The market values Hangzhou Minsheng Healthcare Co Ltd at about 4.2B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥11.67; our models calculate a fair value of ¥3.66 per share.
What do the bullish and bearish scenarios say about 301507?
Our models span a range for Hangzhou Minsheng Healthcare Co Ltd: cautious scenario ¥3.52, base ¥3.66, optimistic ¥4.02 per share (as of Nov 5, 2026, price ¥11.67). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301507?
Hangzhou Minsheng Healthcare Co Ltd trades at a price-to-earnings ratio of 44.9 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥3.66 is built from several models across several years. Other multiples: P/B 2.6, P/S 4.6, EV/EBITDA 30.1.
How solid is the balance sheet of Hangzhou Minsheng Healthcare Co Ltd (301507)?
Balance-sheet figures for Hangzhou Minsheng Healthcare Co Ltd (as of Nov 5, 2026): return on equity 5.3%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 301507 from its 52-week high?
Hangzhou Minsheng Healthcare Co Ltd trades at ¥11.67, about 34% below its 52-week high of ¥17.57 and 3% above the low of ¥11.29 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥3.66 is for.
Which stocks are comparable to Hangzhou Minsheng Healthcare Co Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hangzhou Minsheng Healthcare Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price ¥11.67, calculated fair value ¥3.66 (−69%), Quality Score 43/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301507 calculated?
We run Hangzhou Minsheng Healthcare Co Ltd through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥3.66 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Hangzhou Minsheng Healthcare Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The closing price on Nov 6, 2026 was ¥11.67. Our model-based fair value is ¥3.66, about 69% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hangzhou Minsheng Healthcare Co Ltd right now?
The price sits above even our optimistic bull case (¥4.02). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (¥3.52 to ¥4.02), unusually little disagreement for a valuation.
Key figures of Hangzhou Minsheng Healthcare Co Ltd
How large is the market capitalisation of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The market capitalisation of Hangzhou Minsheng Healthcare Co Ltd is 4.2B CNY (≈ $624M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The price-to-sales ratio of Hangzhou Minsheng Healthcare Co Ltd is 4.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hangzhou Minsheng Healthcare Co Ltd (301507)?
Earnings per share at Hangzhou Minsheng Healthcare Co Ltd are ¥0.2600 (price ÷ EPS = P/E 44.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The dividend yield of Hangzhou Minsheng Healthcare Co Ltd is 1.3% (payout 57.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The net margin of Hangzhou Minsheng Healthcare Co Ltd is 9.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The return on equity (ROE) of Hangzhou Minsheng Healthcare Co Ltd is 5.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hangzhou Minsheng Healthcare Co Ltd (301507)?
On an EBIT basis the return on assets of Hangzhou Minsheng Healthcare Co Ltd is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The operating margin of Hangzhou Minsheng Healthcare Co Ltd is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hangzhou Minsheng Healthcare Co Ltd (301507)?
Revenue at Hangzhou Minsheng Healthcare Co Ltd is growing +30.0% versus a year earlier (3y avg +12.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hangzhou Minsheng Healthcare Co Ltd (301507)?
Earnings per share at Hangzhou Minsheng Healthcare Co Ltd are growing −97.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hangzhou Minsheng Healthcare Co Ltd (301507) generate?
The free cash flow of Hangzhou Minsheng Healthcare Co Ltd is −19.2M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Hangzhou Minsheng Healthcare Co Ltd in the live analysis
One click puts Hangzhou Minsheng Healthcare Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026